Submit Abstracts

Deadline for Abstract Submission : May 9(FRI), 2025
Notification of Acceptance : July 7 (MON), 2025

Submitted abstracts will be reviewed by the Scientific Program Committee. The presentation type may possibly be changed following review by the Scientific Committee.

Abstract submission does not constitute registration, and presenters are required to register for the conference separately. Please carefully read the guidelines before submitting your abstract.

Steps for Abstract Submission

  1. Step 01Click the Abstract Submission button
  2. Step 02Sign up or Log in to KSMO 2025
  3. Step 03Fill out Participant Info and Click “Add”
  4. Step 04Complete Abstract Submission and Author Info Section
  5. Step 05Save and Review the Abstract

※ After submission, you can review and modify your abstracts at 'My page-Abstract Submission' until the submission deadline.

Abstract Submission Guidelines

  • Please select the correct abstract type.
    Any problems or disadvantages arising from the incorrect selection of abstract type are the responsibility of the submitter.
Regular Abstract “Regular Abstract” refers to all types of oncology-related research that are eligible for submission.
Trials in Progress Abstract “Trials in Progress Abstract” refers to ongoing trials that have not reached prespecified endpoints for analysis that are eligible for submission. |Trials in Progress abstracts that include results or preliminary data will be rejected without further review.

It should be organized according to two sections: Backgrounds and Methods.
Encore Abstract “Encore Abstract” refers to abstracts presented in another congress after September 27, 2024, but with updated data.

• Encore submissions must have been presented solely in abstract form, including publication in conference proceedings. (Submissions which have already been published in the full publication form in journals will NOT be accepted.)

• Include significant additional data from the previous presentation (as determined by the review committee).

• Include the abstract title, co-authors listed, the full abstract, and indicate if this is an encore presentation and, if so, where it was previously presented. This information should be presented both in the abstract and on the poster. It is the sole responsibility of the author to follow these rules. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
해외 지원 의무 초록 This type is only for KSMO Members.
  • Abstracts must be written in clear English
  • Abstracts should be no more than 2,600 characters including spaces for the total of abstract body. (NOT including abstract title, author names and institutions)
  • Research work to be presented should be original and not already published as a full paper. The content of the abstract may have been presented at another prior meeting, but you are encouraged to add new information/data
  • An abstract should include a title, author's name and affiliation, body, and keywords.
Title Abstract title should be less than 30 words. Spaces do not count as characters.
Author You can enter up to 30 authors.
Abstract Body The abstract body text should be structured chronologically into four sections: Background, Methods, Results, and Conclusions.
In the case of a “Trials in Progress Abstract,” it should be organized according to two sections: Background and Methods.
Keywords 3 keywords which the first word begins with a capital letter.
Tables and Images No tables, graphs or images are allowed.
  • It is the responsibility of the authors to ensure that their text does not contain typos or grammatical errors.
  • Authors have the option of choosing their presentation type (Oral presentation or E-poster). However, the Scientific Program Committee will make the final decision after review.
  • The right to publish your abstract is granted to the KSMO 2025 Organizing Committee.
  • Presenting authors must register for the conference through the website by July 16(Wed), 2025 (KST).

Abstract Categories

  • Breast Cancer 
  • Central Nervous System Tumor  
  • Developmental Therapeutics 
  • Colorectal and Anal Cancer  
  • Stomach Cancer and Esophageal Cancer  
  • Biliary Tract, Liver and Pancreatic Cancer
  • Kidney and Bladder Cancer 
  • Prostate, Testis and Penile Cancer
  • Gynecologic Cancer 
  • Head and Neck Cancer
  • Lung Cancer 
  • Melanoma and Skin Cancer 
  • Etiology, Epidemiology, Prevention and Genetics 
  • Sarcoma
  • Symptom Science, Palliative Care and Others
Breast Cancer Local/Regional Disease
DCIS/LCIS/Premalignant Lesions
Metastatic Disease
Other Breast Cancer
Central Nervous System Tumor Brain Metastases
Primary CNS Tumors–Glioma
Primary CNS Tumors–Non-Glioma
Developmental Therapeutics Antibodies
Immunotherapy
Circulating Biomarkers
Immunobiology
New Targets and New Technologies
Chemotherapy and Antibody-Drug Conjugates
Molecular Diagnostics and Imaging
Pharmacology/Pharmacodynamics/Pharmacogenetics
Tissue-Based Biomarkers
Vaccines
Radiopharmaceuticals
Small Molecules
Colorectal and Anal Cancer Anal Cancer
Colorectal Cancer–Advanced/Metastatic Disease
Colorectal Cancer–Local-Regional Disease
Other Colorectal and Anal Disease
Stomach Cancer and Esophageal Cancer Stomach Cancer–Advanced/Metastatic Disease
Stomach Cancer–Local-Regional Disease
Esophageal Cancer–Advanced/Metastatic Disease
Esophageal Cancer–Local-Regional Disease
Other GI Cancer
Biliary Tract, Liver and Pancreatic Cancer Biliary Tract Cancer–Local-Regional
Biliary Tract Cancer–Advanced/Metastatic Disease
Hepatocellular Carcinoma–Local-Regional Disease
Hepatocellular Carcinoma–Advanced/Metastatic Disease
Pancreatic Cancer–Local-Regional Disease
Pancreatic Cancer–Advanced/Metastatic Disease
Neuroendocrine/Carcinoid
Other GI Cancers
Kidney and Bladder Cancer Kidney Cancer
Urothelial Cancer–Advanced/Metastatic Disease
Urothelial Cancer–Local-Regional Disease
Other GU Kidney and Bladder Cancer
Prostate, Testis and Penile Cancer Germ Cell/Testicular Cancer
Penile Cancer
Prostate Cancer–Advanced Disease
Prostate Cancer–Local-Regional Disease
Other Prostate, Testicular, and Penile Disease
Gynecologic Cancer Cervical Cancer
Ovarian Cancer
Uterine Cancer
Other Gynecologic Cancer
Head and Neck Cancer Advanced/Metastatic Disease
Local-Regional Disease
Other Head and Neck Cancers (Salivary, Thyroid)
Lung Cancer Non–Small Cell Lung Cancer - Local-Regional Disease
Non–Small Cell Lung Cancer - Advanced/Metastatic Disease
Small Cell Lung Cancer
Mesothelioma
Thymic Malignancies
Other Lung Cancers
Melanoma and Skin Cancer Local-Regional Disease
Advanced/Metastatic Disease
Other Melanoma/Skin Cancers
Etiology, Epidemiology, Prevention and Genetics Etiology/Epidemiology
Germline Genetic Testing
Health Promotions/Behaviors
Hereditary Cancer Syndromes
Cancer Prevention
Sarcoma Gastrointestinal Stromal Tumors (GIST)
Bone Tumors
Soft Tissue Tumors
Symptom Science, Palliative Care and Others Cardio-Oncology
End-of-Life Care
Late and Long-Term Adverse Effects
Palliative Care and Symptom Management
Toxicities–Prevention and Management Strategies
Quality Care/Health Services Research
Clinician Burnout and Wellness
Medical Education
Pathobiology of Symptoms
Psychosocial and Communication Research
Survivorship
Geriatric Oncology

Notification of Acceptance

  • All submitted abstracts will be reviewed by the Scientific Committee according to standard review procedures.
  • Abstract acceptance will be notified by email to presenting authors on the notification date.
  • Outstanding abstracts will receive the award! For further details, please refer to the Awards page.

Withdrawal of Abstracts

  • If the presenting author of an accepted abstract does not register by July 16, 2025 (KST), the abstract will be automatically withdrawn from the final program.
  • If you would like to withdraw an abstract, please notify the KSMO 2025 Secretariat (info@ksmoconference.org) by email as soon as possible.

초록 접수 마감일 : 5월 9일(금), 2025
초록 채택 공지일 : 7월 7일 (월), 2025

초록은 온라인으로 제출 가능하며, 제출된 초록은 KSMO 2025 학술위원회의 심사를 거쳐 수락여부가 최종 확정됩니다.

초록 제출과는 별개로 대회 등록을 진행해 주셔야 하며, 발표자는 반드시 별도로 등록해 주셔야 합니다.

초록 접수 방법

  1. Step 01초록접수버튼 클릭
  2. Step 02회원가입 또는 로그인
  3. Step 03개인정보 입력
  4. Step 04초록/저자 정보 입력
  5. Step 05저장 및 수정

※ 초록제출 후, 접수 마감일까지 'My page-Abstract Submission' 페이지에서 확인 및 수정이 가능합니다.

초록 제출 가이드라인

  • 아래의 초록 유형을 잘 확인하시어 적합한 유형을 선택하시기 바랍니다
    잘못된 유형 선택으로 인해 야기되는 문제나 불이익은 제출자에게 있습니다.
Regular Abstract “Regular Abstract” refers to all types of oncology-related research that are eligible for submission.
Trials in Progress Abstract “Trials in Progress Abstract” refers to ongoing trials that have not reached prespecified endpoints for analysis that are eligible for submission. |Trials in Progress abstracts that include results or preliminary data will be rejected without further review.

It should be organized according to two sections: Backgrounds and Methods.
Encore Abstract “Encore Abstract” refers to abstracts presented in another congress after September 27, 2024, but with updated data.

• Encore submissions must have been presented solely in abstract form, including publication in conference proceedings. (Submissions which have already been published in the full publication form in journals will NOT be accepted.)

• Include significant additional data from the previous presentation (as determined by the review committee).

• Include the abstract title, co-authors listed, the full abstract, and indicate if this is an encore presentation and, if so, where it was previously presented. This information should be presented both in the abstract and on the poster. It is the sole responsibility of the author to follow these rules. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
해외 지원 의무 초록 This type is only for KSMO Members.
  • 초록은 영문으로 작성되어야 합니다.
  • 초록은 공백 포함 2600자(2600 Characters) 이내로 작성되어야 합니다. (제목, 저자 정보 제외)
  • 초록은 전체 논문으로 발표되지 않은 연구과제여야 하며, 타 대회에서 발표된 경우, 내용의 일부를 업데이트하여 제출할 것을 권장합니다.
Title 발표제목은 최대 30단어까지 가능하며, 공백은 포함되지 않습니다.
Author 최대 30명까지 입력 가능합니다.
Abstract Body 초록의 본문은 Background, Methods, Results, Conclusions 4가지로 구성되어야 합니다.
단. TIP 초록은 Background, Methods으로 구성됩니다.
Keywords 3개의 키워드를 입력하고, 키워드 시작은 대문자로 시작합니다.
Tables and Images 초록 내 표, 그림, 그래프 삽입은 불가합니다.초록 내 표, 그림, 그래프 삽입은 불가합니다.
  • 문법의 오류 및 오타 등 초록에 대한 모든 책임은 저자에게 있습니다.
  • 초록 제출 시, 발표 타입(Oral 혹은 E-poster)을 선택할 수 있으나, 학술위원회 심사 후 발표 방식은 변경될 수 있습니다.
  • 제출된 초록에 대한 출판 권리는 KSMO 2025 조직위원회에 부여 됩니다.
  • 발표자는 반드시 2025년 7월 16일(수)까지 홈페이지를 통해 대회 등록을 해야 합니다.

초록접수 카테고리

  • Breast Cancer 
  • Central Nervous System Tumor  
  • Developmental Therapeutics 
  • Colorectal and Anal Cancer  
  • Stomach Cancer and Esophageal Cancer  
  • Biliary Tract, Liver and Pancreatic Cancer
  • Kidney and Bladder Cancer 
  • Prostate, Testis and Penile Cancer
  • Gynecologic Cancer 
  • Head and Neck Cancer
  • Lung Cancer 
  • Melanoma and Skin Cancer 
  • Etiology, Epidemiology, Prevention and Genetics 
  • Sarcoma
  • Symptom Science, Palliative Care and Others
Breast Cancer Local/Regional Disease
DCIS/LCIS/Premalignant Lesions
Metastatic Disease
Other Breast Cancer
Central Nervous System Tumor Brain Metastases
Primary CNS Tumors–Glioma
Primary CNS Tumors–Non-Glioma
Developmental Therapeutics Antibodies
Immunotherapy
Circulating Biomarkers
Immunobiology
New Targets and New Technologies
Chemotherapy and Antibody-Drug Conjugates
Molecular Diagnostics and Imaging
Pharmacology/Pharmacodynamics/Pharmacogenetics
Tissue-Based Biomarkers
Vaccines
Radiopharmaceuticals
Small Molecules
Colorectal and Anal Cancer Anal Cancer
Colorectal Cancer–Advanced/Metastatic Disease
Colorectal Cancer–Local-Regional Disease
Other Colorectal and Anal Disease
Stomach Cancer and Esophageal Cancer Stomach Cancer–Advanced/Metastatic Disease
Stomach Cancer–Local-Regional Disease
Esophageal Cancer–Advanced/Metastatic Disease
Esophageal Cancer–Local-Regional Disease
Other GI Cancer
Biliary Tract, Liver and Pancreatic Cancer Biliary Tract Cancer–Local-Regional
Biliary Tract Cancer–Advanced/Metastatic Disease
Hepatocellular Carcinoma–Local-Regional Disease
Hepatocellular Carcinoma–Advanced/Metastatic Disease
Pancreatic Cancer–Local-Regional Disease
Pancreatic Cancer–Advanced/Metastatic Disease
Neuroendocrine/Carcinoid
Other GI Cancers
Kidney and Bladder Cancer Kidney Cancer
Urothelial Cancer–Advanced/Metastatic Disease
Urothelial Cancer–Local-Regional Disease
Other GU Kidney and Bladder Cancer
Prostate, Testis and Penile Cancer Germ Cell/Testicular Cancer
Penile Cancer
Prostate Cancer–Advanced Disease
Prostate Cancer–Local-Regional Disease
Other Prostate, Testicular, and Penile Disease
Gynecologic Cancer Cervical Cancer
Ovarian Cancer
Uterine Cancer
Other Gynecologic Cancer
Head and Neck Cancer Advanced/Metastatic Disease
Local-Regional Disease
Other Head and Neck Cancers (Salivary, Thyroid)
Lung Cancer Non–Small Cell Lung Cancer - Local-Regional Disease
Non–Small Cell Lung Cancer - Advanced/Metastatic Disease
Small Cell Lung Cancer
Mesothelioma
Thymic Malignancies
Other Lung Cancers
Melanoma and Skin Cancer Local-Regional Disease
Advanced/Metastatic Disease
Other Melanoma/Skin Cancers
Etiology, Epidemiology, Prevention and Genetics Etiology/Epidemiology
Germline Genetic Testing
Health Promotions/Behaviors
Hereditary Cancer Syndromes
Cancer Prevention
Sarcoma Gastrointestinal Stromal Tumors (GIST)
Bone Tumors
Soft Tissue Tumors
Symptom Science, Palliative Care and Others Cardio-Oncology
End-of-Life Care
Late and Long-Term Adverse Effects
Palliative Care and Symptom Management
Toxicities–Prevention and Management Strategies
Quality Care/Health Services Research
Clinician Burnout and Wellness
Medical Education
Pathobiology of Symptoms
Psychosocial and Communication Research
Survivorship
Geriatric Oncology

초록 채택 안내

  • 접수된 초록은 심사를 통해 수락여부가 확정되며, 이메일을 통해 발표자에게 안내해 드릴 예정입니다.
  • 우수 초록은 상금 및 상장이 수여됩니다. 자세한 사항은 Awards page.페이지를 참고 부탁 드립니다.

초록철회

  • 수락된 초록의 발표자가 발표자 등록마감일 2025년 7월 16(수)까지 등록하지 않으면, 접수된 초록은 철회됩니다.
  • 초록 철회를 원하실 경우, 사무국(info@ksmoconference.org)으로 연락 부탁드립니다.